These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 349581)

  • 21. Treatable risk factors--hypercholesterolemia, smoking, and hypertension--after myocardial infarction: implications of the coronary drug project data for clinical management. Coronary Drug Project Research Group.
    Prim Care; 1980 Mar; 7(1):175-9. PubMed ID: 6992178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronary thrombolysis and aging.
    Vine DL
    Kans Med; 1990 Feb; 91(2):47-8. PubMed ID: 2181200
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency.
    Sharma GV; Khuri SF; Josa M; Folland ED; Parisi AF
    Circulation; 1983 Sep; 68(3 Pt 2):II218-21. PubMed ID: 6347428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proceedings: A clinical trial of antiplatelet therapy in patients with coronary arterial disease.
    Michaels L; Galbraith PA; Ledwich JR
    Thromb Diath Haemorrh; 1975 Nov; 34(2):598-9. PubMed ID: 1105881
    [No Abstract]   [Full Text] [Related]  

  • 25. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
    Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.
    Lee PY; Chen WH; Ng W; Cheng X; Kwok JY; Tse HF; Lau CP
    Am J Med; 2005 Jul; 118(7):723-7. PubMed ID: 15989905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenylbutazone and aspirin in osteoarthritis: a controlled study.
    Curr Ther Res Clin Exp; 1975 May; 17(5):444-51. PubMed ID: 805028
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effects of medical therapy on long-term survival in ischemic heart disease].
    Caruzzo C; Sechi A; Monti C; Campagna G; Spinnler MT
    Minerva Cardioangiol; 1984 Dec; 32(12):887-93. PubMed ID: 6152332
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiac death prevention in post-myocardial infarction patients: a review.
    Boissel JP; Leizorovicz A; Faucomprez C
    Acta Cardiol Suppl; 1980; (25):147-79. PubMed ID: 6103625
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of nadolol in coronary disease].
    Tkaczewski W; Goch JH; Dziekański S
    Kardiol Pol; 1983; 26(3):215-9. PubMed ID: 6138456
    [No Abstract]   [Full Text] [Related]  

  • 33. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.
    Jneid H; Bhatt DL; Corti R; Badimon JJ; Fuster V; Francis GS
    Arch Intern Med; 2003 May; 163(10):1145-53. PubMed ID: 12767950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results of Intencordin treatment of patients with coronary artery disease].
    Adamska-Dyniewska H; Goch JH; Gajewska B
    Wiad Lek; 1973 Oct; 26(20):1937-40. PubMed ID: 4587344
    [No Abstract]   [Full Text] [Related]  

  • 35. Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
    Guptha S
    Curr Opin Lipidol; 1995 Oct; 6(5):251-3. PubMed ID: 8520845
    [No Abstract]   [Full Text] [Related]  

  • 36. Influence of treatment adherence in the coronary drug project.
    N Engl J Med; 1981 Mar; 304(10):612-3. PubMed ID: 7005674
    [No Abstract]   [Full Text] [Related]  

  • 37. Brief description of the Coronary Drug Project and other studies.
    Canner PL
    Control Clin Trials; 1983 Dec; 4(4):273-80. PubMed ID: 6373137
    [No Abstract]   [Full Text] [Related]  

  • 38. [Efficiency of carbocromen in coronary heart disease--an application problem?].
    Rupprecht E
    ZFA (Stuttgart); 1977 Jun; 53(17):1010-4. PubMed ID: 329600
    [No Abstract]   [Full Text] [Related]  

  • 39. Aspirin in myocardial ischemia: why, when, and how much?
    Mehta JL; Conti CR
    Clin Cardiol; 1989 Apr; 12(4):179-84. PubMed ID: 2653681
    [No Abstract]   [Full Text] [Related]  

  • 40. The Coronary Drug Project. Further aspects of data analysis.
    Canner PL
    Control Clin Trials; 1983 Dec; 4(4):485-503. PubMed ID: 6675897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.